Kornimate/medical-research-clean huggingface dataset:
supplementation of glutamine and fish oil versus placebo in patients with heart failure

Conditions: Heart Failure

Summary: the aim of this study is to determine whether supplementation of glutamine and fish oil can improve peripheral skeletal muscle function and metabolism in patients with heart failure. the investigators propose a randomized, double-blind, placebo controlled study comparing the combined supplementation of fish oil and glutamine with placebo in patients with stable heart failure. 30 patients with heart failure will be randomized to either receiving 6.5 g fish oil/d and 8 g glutamine/d (n=15) or placebo (n=15) for 90 days. the primary outcome in this study is the change in muscle functional capacity measured as changes in maximum muscle strength and fatigability, peak vo2 and exercise time after supplementation. a secondary outcome is the measurement of systemic and local markers of inflammation.


Eligibility criteria:
inclusion criteria: * age greater than 18 years, * left ventricular ejection fraction less than or equal to 35%, * stable on standard hf medications, and * optimal medical therapy. exclusion criteria: * major cardiovascular events, * procedures in the last 6 months, * dementia, * presence of cardiovascular diseases that may lead to harm if the patient took part in the study (congenital heart disease, long qt syndrome, hypertrophic cardiomyopathy, active myocarditis).

Keywords: heart failure skeletal muscle function metabolism inflammation glutamine fish oil muscle function
predictive value of 99mtc- albumin spheres before 90y- sir therapy

Conditions: Colorectal Cancer; Liver Metastases

Summary: the purpose of this study is to assess the predictive value of 99mtechnetium (tc)- labeled albumin in macroaggregates (maa) and in microspheres (b20) injected into the common hepatic artery for the distribution of 90yttrium- selective internal radiotherapy (sirt)-spheres (sir- spheres).

patients with metastases of colorectal tumors will be included into this study provided that they are scheduled for 90y sir spheres therapy for clinical reasons. before 90y sir spheres therapy, patients will receive a diagnostic examination with injection of maa (group a) or b20 (group b) into the common hepatic artery to rule out a relevant shunt volume to the lung or other extra-hepatic locations (e.g., stomach) as recommended by the manufacturer. after the diagnostic scan, therapy with sir- spheres will be conducted in 2 separate sessions with selective injection of 90y labeled sir spheres into the right and left hepatic artery at two separate occasions (routine procedure at the university of magdeburg, germany). in addition, therapeutic sessions will include the selective injection of maa or b20 into the right / left hepatic artery according to a predefined plan (either alone or as a mixture with the sir spheres).the intra-hepatic distribution of 90y labeled sir spheres will be assessed using "bremsstrahlen"- single- photon- emission- computed- tomography (spect)- imaging, the distribution of maa and b20 will be assessed using spect imaging.

Eligibility criteria:
inclusion criteria: * age: between 18 and 85 years * if female, postmenopausal or surgically sterilized * liver metastases of a colorectal tumor in both liver lobes * scheduled for therapy with 90y sir spheres for clinical reasons * life expectancy longer than 6 months * willing and able to undergo all study procedures * having voluntarily provided written and fully informed consent exclusion criteria: * presenting with a contraindication to 90y sir spheres therapy * variants of the arterial hepatic blood supply which interfere with the objectives of this study (e.g., variants of michel) * women who are pregnant, lactating or who are of childbearing potential * patients being clinically unstable * uncooperative, in the investigator's opinion * any contraindication to sirt treatment * any concomitant chemotherapy * shunt to the lung \>10% * shunt to any extrahepatic organ (except the lung) * having been previously enrolled in this study * participating in another prospective clinical trial

Keywords: liver metastases maa b20 sir spheres spect intra-hepatic distribution
efficacy and safety of tak-438 for the prevention of recurrent gastric or duodenal ulcers during therapy of low-dose aspirin

Conditions: Gastric Ulcers; Duodenal Ulcers

Summary: the purpose of this study is to evaluate the efficacy of tak-438, once daily (qd) compared to ag-1749 (lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.


Eligibility criteria:
inclusion criteria: 1. participants who require continuous low-dose aspirin therapy during the treatment period with the study drug 2. participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed 3. outpatient (including inpatient for examinations) exclusion criteria: 1. participants scheduled to change the type and dosage regimen of low-dose aspirin 2. participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed 3. participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology 4. participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery 5. participants with a previous or current history of zollinger-ellison syndrome, or other gastric acid hypersecretion disorders 6. participants with a previous or current history of aspirin-induced asthma

Keywords: drug therapy
a randomized clinical trial comparing chi-beam with beam regimen combined with asct for the treatment of nd ptcl

Conditions: Newly Diagnosed Peripheral T-cell Lymphoma

Summary: the goal of this clinical trial is to compare chi-beam with beam regimen combined with asct for the treatment of nd ptcl. the main question it aims to answer are: •whether chi-beam improves patient survival compared to beam group participants will be given beam or chi-beam before asct. researchers will compare the efficacy and safety of the two groups.

this is a prospective, multicenter, randomized controlled, open trial. the primary endpoint was 2-year pfs the secondary endpoint was： 2-year overall survival (os). cr rate at 3 months post-transplant evaluation hematopoietic reconstitution time non-recurrent mortality (nrm)

Eligibility criteria:
inclusion criteria: 1. pathologically diagnosed patients with newly treated ptcl (including nt/ k-cell lymphoma), except for alk (+), have cr or pr after first-line treatment; 2. renal function needs to be satisfied: creatinine clearance ≥80ml/min, creatinine less than 160μmol/l; liver function requirements: alt and ast≤2 times the upper limit of normal; total bilirubin ≤2 times the upper limit of normal; lung function should meet: fev1, fvc, dlco≥50% predictive value; cardiac function must be satisfied: left ventricular ejection fraction ≥50%, asymptomatic arrhythmia. 3. age between 18 and 65 years old, male and female; 4. ecog physical strength score 0-1; 5. neutrophil absolute value ≥1.5×109/l, platelets ≥ 70×109/l, hemoglobin ≥ 90g/l; number of cd34+ cells ≥ 2.0×106/kg body weight; 6. expected survival time ≥3 months; 7. voluntarily sign written informed consent. exclusion criteria: 1. lymphoma involving the central nervous system 2. active hepatitis b or c virus infection; 3. active infection; 4. hiv infected persons; 5. evidence of cirrhosis or liver fibrosis; 6. ecg showed qtc \> 500ms; 7. persons with mental disabilities/unable to obtain informed consent; 8. patients with drug or chronic alcohol abuse that may affect the evaluation of study results; 9. pregnant and lactating women and women of childbearing age who do not want to take contraceptive measures; 10. the researcher determines that it is not suitable to participate in this study

Keywords: ptcl chidemide
total neoadjuvant therapy for locally advanced rectal cancer

Conditions: Rectal Cancer

Summary: the concurrent neoadjuvant chemoradiation therapy is standard care for local advanced rectal cancer (larc), however, this regimen may induce sorts of adverse events, and part of them even more severer. a number of pilot studies had shown high rate of complete resection after neoadjuvant chemotherapy alone, but the results did not increase the ratio of pathological complete response (pcr), which was associated with overall survival (os). here, the investigators adopt the three active cytotoxic agents (fluorouracil, oxaliplatin, irinotecan, folfoxiri) as the neoadjuvant chemotherapy regimen to replace the concurrent chemoradiation and to improve the ratio of pcr further.

this is a multicenter, phase ii trial to assess the efficacy/safety of triplet regimen (folfoxiri) for patients with larc. after 4 cycles of folfoxiri and 2 weeks later, the patients will be evaluated by senior radiologist, oncologist and surgeon through pelvic mri, ct and positron emission computed tomography (pet-ct). the patients will go to surgery (tme) if the tumor response is good enough to have complete resection under the decision of mdt,otherwise, the patients will receive pelvic radiotherapy(45grey/25fraction and 5.4grey/3fraction boost to the tumor bed) combined with capecitabine(625mg/m\^2, bid po, d1-5, qw), and additional four cycles of modified folfox6 (mfolfox6) or oxaliplatin 135mg/m²plus capecitabine 1.0/m² bid po(xelox) of each 3 weeks cycle for 2 cycles chemotherapy before tme. all patients will receive 6-8 cycles of mfolfox6 or 4-5 cycles xelox as adjuvant chemotherapy after tme.

Eligibility criteria:
inclusion criteria: * age ≥ 18 to 75 years at diagnosis * diagnosis of rectal adenocarcinoma * ecog status: 0～1 * clinical stage ii (t3-4, n0) or stage iii (t1-4, n1-2) * adequate bone marrow, hepatic and renal function as assessed by the following laboratory requirements conducted within 7 days of starting study treatment: * leukocytes ≥ 4.0 x109/ l, * absolute neutrophil count (anc) ≥ 2.0 x109/ l * platelet count ≥ 100 x109/ l, * hemoglobin (hb) ≥ 9g/ dl. * total bilirubin ≤1.5 x the upper limit of normal (uln). * alanine aminotransferase (alt) ≤ 3 x uln * aspartate aminotransferase (ast) ≤ 3 x uln. * serum creatinine ≤ 1.5 x the uln. * signed informed consent; exclusion criteria: * patient had received pelvic radiotherapy * patient had received systemic chemotherapy * pregnant and nursing women * had metastatic disease * uncontrolled co-morbid illnesses or other concurrent disease * patient had second malignant disease within 5 years * patients refused to signed informed consent.

Keywords: local advanced rectal cancer total neoadjuvant therapy folfoxiri
therapeutic effect of egf cream for cutaneous adverse event of egfr inhibitors

Conditions: Drug-Related Side Effects and Adverse Reactions; Epidermal Growth Factor

Summary: the purpose of this study is to evaluate the therapeutic efficacy of topical egf cream for dermatologic adverse events related to egfr inhibitors.

epidermal growth factor receptor(egfr) is involved in cell proliferation and is overexpressed or abnormally activated in malignant tumors originating from the colon, breast, ovary, pancreas, and lung. egfr tyrosine kinase inhibitor(tki), gefitinib, erlotinib, and afatinib have been for the treatment of cancer associated with egfr gene mutation. in addition, monoclonal antibodies to egfr, such as cetuximab and panitumumab, have been used as a chemotherapy for rectal cancer without ras gene mutation and advanced head and neck cancer. the incidence of cutaneous toxicity of egfr inhibitors is reported to be 75-80%. clinical features include acneform folliculitis, xerosis, paronychia, and itching. of these, about 10% of patients with grade 3 or greater have a detrimental effect on quality of life and adherence to treatment, resulting in impaired therapeutic results. there have been many attempts to prevent or treat such skin toxicity. however, there has been no scientifically proven treatment until now. there is a growing interest in the role of egf emulsifiers in the treatment of skin adverse effects of egfr inhibitors, as a result of studies that improve acne significantly compared to placebo. the purpose of this study is to evaluate the therapeutic efficacy of egf cream in the treatment of skin adverse effects in patients with malignant tumors treated with egfr inhibitor (tki or monoclonal antibody).

Eligibility criteria:
inclusion criteria: * patients who received egfr inhibitors (gefitinib, erlotinib, afatinib, cetuximab, etc.) for malignant tumors * patients with egfr inhibitor-associated skin reactions: national cancer institute's common terminology criteria for adverse events (nci-ctcae v4.03) grade 2, 3 patients * patients who can understand and follow the protocol * patients who spontaneously agreed to the study exclusion criteria: * nci-ctcae grade 4 patients requiring systemic drug therapy * those with a history of antibiotic treatment, local and systemic steroid therapy within 4 weeks for reasons other than egfr inhibitors * patients with existing acne history * patients who have already received anti-egfr therapy

Keywords: epidermal growth factor
białystok plus - polish longitudinal university study

Conditions: Cardiovascular Diseases; Diabetes; Neuro-Degenerative Disease; Obesity; Pulmonary Disease; Neoplastic Disease

Summary: the main goal of the study is to provide a unique multidimensional picture of the health of the population with simultaneous optimal standards of sampling, processing and storing of data and biomaterial that will allow discovering novel mechanisms in the development and progression of common civilization diseases. in the effect it will improve prevention, diagnosis and treatment.

one of the objectives of this project is to obtain comprehensive information on the health status (including subclinical disorders), genomics, risk factors, health behavior and sociodemographic data from large, representative sample of population of białystok city inhabitants. the study will assess many systems, the major emphasis will be given to the most common diseases associated with modern lifestyle (civilization diseases): cardiovascular, metabolic and endocrine, neurodegenerative, neoplastic and pulmonary. there are many interactions between them that might be missed when not analyzed together. apart from those most common diseases we will also asses others, including allergies, airway dysfunction - both upper and lower, urinary incontinency, gastrointestinal disorders, eye diseases. there may be many common underlying mechanisms of the diseases that now seem to be distant and independent, because of insufficient knowledge. health status assessment will refer to many areas of medicine and will include clinical data, medical images, as well as biological samples and voice recording samples. we plan to combine imaging (fundoscopy, ultrasound examinations of heart, vessels, thyroid, liver) with state of the art functional studies (age measurement, pulse wave velocity, central pressure, plethysmography with the analysis of diffusing capacity of lung for carbon monoxide and no concentration, spiroergometry, oral glucose tolerance test. voice samples will be analyzed in the speech analysis software, it will help in the diagnosis of civilization diseases such as diabetes, depression, and atherosclerosis. participants will fill in detailed questionnaires that will provide information about their family history, dietary habits, socioeconomic status, stress coping strategies, lifestyle, exposure to harmful environment, various symptoms, history of diagnosed diseases and treatment. the study is designed as prospective, so in the future, additional information on occurrence of diseases or deaths will allow to estimate disease incidence, morbidity or mortality in studied population.

Eligibility criteria:
inclusion criteria: * inhabitants of bialystok (randomly selected from the registry of bialystok inhabitants) * age 20-80 exclusion criteria: * disagreement of the invited person

Keywords: civilization diseases cardiovascular risk factor population study intestinal microbiome oral microbiome
spironolactone with patiromer in the treatment of resistant hypertension in chronic kidney disease

Conditions: Hyperkalemia; Resistant Hypertension

Summary: the purpose of this study is to determine if patiromer treatment in chronic kidney disease (ckd) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).

approximately 290 eligible participants with \[chronic kidney disease (ckd) on stable doses of medication\] will be randomly assigned to receive a patiromer or placebo starting dose of two packets a day, once a day. all eligible participants will undergo a screening/run-in period (up to 4 weeks) to determine eligibility for study entry. eligible participants will be randomized and treated for 12 weeks (treatment period) and followed for 2 weeks after completing the patiromer or placebo treatment. there are 8 planned clinic visits during the treatment period and one planned visit two weeks after the last dose of patiromer or placebo (follow-up period). the dose of patiromer or placebo may be increased or decreased (titrated) based on participants' individual potassium response.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * taking at least three medications for blood pressure (one a diuretic) * uncontrolled high blood pressure * abnormal kidney function (with-egfr, a measure of kidney function, of 25 - ≤ 45 ml/min/1.73m2 * normal blood serum potassium in a specific range (4.3 - 5.1 meq/l) exclusion criteria: * history of untreated known causes of high blood pressure, excluding kidney disease (not ckd) * inability to measure bp * not taking high blood pressure medications as prescribed medications * recent change in renal function (in the past 3 months) which has required hospitalization or dialysis * renal transplant * history of cancer within past 12 months * recent cardiovascular event with last 3 months * clinically significant abnormalities of heart rhythm (ventricular arrhythmia or atrial fibrillation with uncontrolled heart rate) * inability to take study medication * alcoholism

Keywords: treatment of hyperkalemia hyperkalemia potassium chronic kidney disease hypertension resistant hypertension spironolactone
evaluation of healthcare waste management practices and problems among primary and secondary hospitals

Conditions: Healthcare Associated Infection

Summary: healthcare waste is defined as the total waste stream from a healthcare facility. most of it (75-90%) is similar waste to domestic waste and is known as healthcare general waste and is made up of paper, plastic packaging, food preparation etc. but as a similar proportion (10-25%) is hazards waste and requires special treatment. if these two categories of wastes are not separated properly then the entire volume of healthcare waste is considered as infectious and hazardous to human health and can result in disease and injury so it is necessary to set up a safe and integrated management system. in this cross-sectional study public hospitals of mianwali city will be selected by simple random sampling for observation of practices of hospital waste management.

the data will be collected through structured questionnaire and possibly on-sit quantitative data on waste management practices, types of waste, compliance with regulations, and perceived challenges.

Eligibility criteria:
inclusion criteria: * operation theatre staff * intensive care staff and labour room staff and laboratory room staff will be included. * doctors, nurses, nursing assistants, ot technician, maid's helpers, and sanitary workers. exclusion criteria: * management staff will be excluded.
duration between drainage and ureteroscopic lithotripsy

Conditions: Ureter Stone; Renal Stone; Ureteric Obstruction

Summary: this study will be conducted to compare early (seven days) versus delayed (14-21 days) definitive ureteroscopic lithotripsy after initial drainage for obstructing ureteral or renal stones associated with infection.

all the study participants will be monitored during the early post-operative period for post-operative pain and complications. the rate and grade of reported complications will be determined according to modified dindo-clavian grading system. after ensuring safe status for discharge, all patients will be reassessed at the outpatient department after 4 weeks by ncct to assess stone free status.

Eligibility criteria:
inclusion criteria: 1. obstructing ureteral or renal stone \<20 mm. 2. associated clinical evidence of acute upper urinary tract infection based on systemic inflammatory response syndrome (sirs). exclusion criteria: 1. history of endoscopic instrumentation to the urinary tract in the last 4 weeks prior to presentation. 2. bilateral obstructed kidneys necessitating bilateral drainage. 3. associated emphysematous pyelonephritis or perinephric abscess.

Keywords: ureteroscopy sepsis infectious complications ureteric calculi renal calculi
comparison of segmentectomy versus lobectomy for non-small cell lung cancer ≤ 2 cm in the middle third of the lung field

Conditions: Lung Neoplasms; Surgery

Summary: this study aims to investigate whether segmentectomy had non-inferiority long-term oncological effects (disease-free survival and overall survival) compared with lobectomy in the treatment of patients with early-stage non-small cell lung cancer ≤ 2 cm in the middle third of lung field.

nowadays, the role of segment resection in the treatment of non-small cell lung cancer ≤ 2 cm in the outer third of the lung field has been evaluated in multiple studies. recently, professor hisao asamura released the long-term results of the jcog0802 project in aats 2021. segmentectomy had a higher 5-year overall survival (94.3% vs. 91.1%) than lobectomy (p \ 0.5) in the outer third of the lung field. however, a substantial portion of lung nodules was not located in the outer third, but the middle third of the lung field. whether segmentectomy has non-inferiority long-term oncological effects compared to lobectomy for early-stage non-small cell lung cancer ≤ 2 cm in the middle third of lung field remains unclear. this randomized controlled trial study aims to investigate whether segmentectomy has non-inferiority long-term oncological effects compared to lobectomy for early-stage non-small cell lung cancer ≤ 2 cm in the middle third of the lung field.

Eligibility criteria:
inclusion criteria: 1. patient aged 18-75 years old; 2. 6 mm ≤ tumor size ≤ 20 mm; 3. 0.25 \< ctr \< 1; 4. center of tumor located in the middle third of the lung field; 5. ecog score of 0,1 or 2; 6. lung function (fev1 ≥ 1 l and ≥ 70%); 7. both lung segmentectomy and lobectomy could achieve r0 resection; 8. no serious cardiopulmonary complications, and could withstand both lung segmentectomy and lobectomy; 9. no hilus pulmonis and mediastinal lymph node metastasis and no distant metastasis; 10. single tumor nodule or the concomitant nodule \< microinvasive tumor; 11. written informed consent. exclusion criteria: 1. the tumor nodule is located in right middle lobe; 2. a history of other malignancies in the last 5 years (exclusion of early-staged thyroid cancer); 3. have received preoperative anti-tumor therapy, including prior chemotherapy, radiation therapy, target therapy and so on; 4. a serious mental illness; 5. pregnant and lactating women; 6. congestive heart failure, myocardial infarction, severe stenosis of coronary artery within recent 6 months; 7. with the history of cerebral infarction or cerebral hemorrhage within 6 months; 8. with the history of sustained systemic corticosteroid therapy within 1 month; 9. the predicted surgical margin is less than 2 cm or the maximum diameter of the tumor at the 3d-ctba 10. other unsuitable situations;

Keywords: non-small cell lung cancer segmentectomy lobectomy the middle third of the lung field